Carboplatinum is the second generation platinum anticancer drug with nonspecific cell cycle and similar effect to alkylating agent. A decrease in carboplatinum hemotoxicity was detected in experiments on C57B1 mice treated with the drug in combination with indralin (urgent radioprotector). Carboplatinum in a dose of 125 mg/kg, injected intraperitoneally, caused 80-100% death; the median term of death was 6 days (3-17)[3]. S. typhimurium A1-R and CAR (Carboplatinum) moderately inhibited tumor growth compared to the untreated group on day 15 (P < 0.001 and P < 0.001, respectively). S. typhimurium A1-R combined with CAR inhibited the tumor growth significantly more compared to S. typhimurium A1-R monotherapy or CAR monotherapy on day 15 (P = 0.004 and P = 0.001, respectively)[4]. In vitro synergistic efficacy of MK-2206 when combined with carboplatinum and paclitaxel in the three cell lines examined. Efficacy was dose dependent[5]. Sequential therapy with carboplatin plus paclitaxel followed by topotecan, all given at standard doses, is feasible and provides favorable response rates[6].
Carboplatin/卡铂 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Nude mice
Breast cancer dormancy model
Intraperitoneal injection
2 mg/kg
Administered on days 3 and 5, duration of 7 days
KMT2B and KMT2D KD BCCs showed significantly reduced metastasis to the brain, indicating that targeting H3K4 can reduce brain metastasis.
Cell Commun Signal. 2024 Feb 12;22(1):119.
Nude mice
OVCAR5 xenograft model
Intraperitoneal injection
50 mg/kg
Once a week for 4 weeks
To evaluate the effect of PFK158 in combination with carboplatin, results showed that PFK158 combined with carboplatin significantly inhibited tumor growth and metastasis
J Exp Clin Cancer Res. 2021 Jun 3;40(1):182.
BALB/c nude mice
IGROV1 xenograft tumor model
Intraperitoneal injection
20 mg/kg or 60 mg/kg
Every 2 days for 2 weeks
Carboplatin treatment significantly increased SENP1 expression in IGROV1 xenograft tumors
搜索
